Athelas, a Mountain View–based healthcare technology company founded in 2014, has raised a total of $136 million in funding, including a $132 million Series A round in January 2022 at a $1.5 billion valuation, led by General Catalyst and Tribe Capital. Earlier backers include Sequoia Capital, Y Combinator, and Initialized Capital. Athelas builds innovative diagnostic and monitoring solutions, such as its FDA-cleared white blood cell counter and connected health device, to help chronically ill patients monitor vital signs like blood pressure, weight, and glucose from home.